MedPath

Alpha Tau Receives FDA TAP Acceptance to Expedite Alpha DaRT for Recurrent Glioblastoma

• Alpha Tau Medical has been accepted into the FDA's Total Product Life Cycle (TPLC) Advisory Program (TAP) to accelerate market access for Alpha DaRT in recurrent glioblastoma multiforme (GBM). • The TAP program aims to expedite patient access to innovative medical devices by providing early and strategic communication with the FDA and facilitating engagement with key stakeholders. • Alpha DaRT is designed for potent alpha-irradiation of solid tumors through intratumoral delivery of radium-224 impregnated sources, targeting tumor cells while sparing healthy tissue. • This acceptance follows Alpha Tau's prior FDA Breakthrough Device Designation for Alpha DaRT in GBM, highlighting the urgent need for innovative therapies for this aggressive cancer.

Alpha Tau Medical Ltd. has announced its acceptance into the U.S. Food and Drug Administration's (FDA) Total Product Life Cycle (TPLC) Advisory Program (TAP) to expedite market access for Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM). This follows the company's previous receipt of Breakthrough Device Designation from the FDA for this indication.

Expediting Access to Innovative Therapies

The TAP program is designed to accelerate patient access to promising medical devices not currently on the market. It facilitates early, frequent, and strategic communications with the FDA and engagement with other key parties. A dedicated team of FDA TAP advisors provides tailored assistance in areas including product lifecycle regulation, payer coverage policies, and integration of patient insights.
"As Alpha Tau intensifies its ongoing focus on treating internal organs with tremendous unmet need, and advances further towards commercialization of the Alpha DaRT, this exciting announcement comes at exactly the right time," said Alpha Tau Chief Executive Officer Uzi Sofer. "With an estimated 14,000 new GBM diagnoses per year in the U.S., and exceedingly low five-year survival rates, the need to expedite access to new innovative therapies is clear."

About Alpha DaRT

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors. It involves intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released and disperse while emitting high-energy alpha particles, with the goal of destroying the tumor. The alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Glioblastoma Multiforme (GBM)

Glioblastoma multiforme is one of the most aggressive and challenging cancers to treat. The acceptance into the FDA's TAP program represents a significant step forward in the development and potential commercialization of Alpha DaRT as a treatment option for patients with recurrent GBM, addressing a critical unmet need in oncology.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Targeted Alpha Therapy Shows Promise in Expanding Cancer Treatment Landscape

Targeted alpha therapy (TAT) is emerging as a promising cancer treatment, delivering localized radiation to tumor cells while minimizing harm to healthy tissues.
The FDA approval of Xofigo in 2013 for advanced prostate cancer marked a pivotal moment, spurring research into TAT for various solid tumors and hematological malignancies.

FDA Approves BridgeBio's Attruby for ATTR-CM, Reducing Cardiovascular Death and Hospitalization

The FDA has approved Attruby (acoramidis), an oral TTR stabilizer developed by BridgeBio, for treating adults with ATTR-CM.
Attruby demonstrated a significant reduction in cardiovascular death and cardiovascular-related hospitalizations in the Phase 3 ATTRibute-CM study.

Alpha Tau Medical's Alpha DaRT Receives FDA Advisory Program Acceptance and Advances Clinical Trials

Alpha Tau Medical's Alpha DaRT therapy has been accepted into the FDA's Total Product Life Cycle Advisory Program for recurrent glioblastoma multiforme (GBM).
A clinical trial has begun in Israel to assess the safety of Alpha DaRT in treating recurrent lung cancer using endobronchial ultrasound.

Alpha Tau Medical's Alpha DaRT Receives FDA Support and Advances in Clinical Trials

Alpha Tau Medical's Alpha DaRT therapy gains FDA acceptance into the Total Product Life Cycle Advisory Program for recurrent glioblastoma multiforme, aiming to expedite market access.
Clinical trials progress with the first patient treated in a recurrent lung cancer study in Israel, assessing the safety and feasibility of Alpha DaRT delivery via endobronchial ultrasound.

FDA Approves Autolus' CAR-T Cell Therapy Aucatzyl for Relapsed/Refractory B-ALL

The FDA has approved Autolus Therapeutics' Aucatzyl, a CAR-T cell therapy, for treating relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in adults.
Aucatzyl's approval was based on the FELIX clinical trial, which demonstrated encouraging remission rates and manageable side effects in adult r/r B-ALL patients.

FDA Approves Alpha Tau's IDE for Alpha DaRT Study in Immunocompromised cSCC Patients

Alpha Tau Medical's Investigational Device Exemption (IDE) has been approved by the FDA for a multi-center study of Alpha DaRT in immunocompromised patients with recurrent cutaneous Squamous Cell Carcinoma (cSCC).
The study, led by Emory University's Winship Cancer Institute, will enroll up to 28 patients across 8 U.S. institutions, focusing on those with weakened immune systems, excluding diabetes.

Poseida Therapeutics' P-BCMA-ALLO1 Receives FDA RMAT Designation for Relapsed/Refractory Multiple Myeloma

Poseida Therapeutics' P-BCMA-ALLO1, an allogeneic CAR-T cell therapy, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA.
The RMAT designation is based on encouraging Phase 1 clinical data, highlighting P-BCMA-ALLO1's potential efficacy and safety in multiple myeloma patients.

FDA Clears Investigational New Drug Application for Adaptin Bio's Glioblastoma Therapy APTN-101

The FDA has cleared Adaptin Bio's investigational new drug application for APTN-101, a novel therapy for glioblastoma, a grade 4 malignant glioma.
APTN-101 utilizes Adaptin Bio's BRiTE platform to target EGFRvIII, a protein associated with aggressive brain tumors, and enhance T-cell delivery to the brain.

FDA Grants Priority Review to Tabelecleucel for EBV+ PTLD Treatment

The FDA has accepted Atara Biotherapeutics' BLA for tabelecleucel, a monotherapy for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Tabelecleucel's BLA received Priority Review, setting a PDUFA target action date of January 15, 2025, highlighting the urgent need for new treatments.

FDA Grants Priority Review to Lecanemab for Early Alzheimer's Treatment

The FDA has accepted Eisai's Biologics License Application (BLA) for lecanemab, an anti-amyloid beta protofibril antibody, for treating mild cognitive impairment due to Alzheimer's disease.
Lecanemab has been granted Priority Review, setting a PDUFA action date for January 6, 2023, potentially expediting access for patients with early Alzheimer's.

Reference News

[1]
Alpha Tau Medical's Alpha DaRT Receives FDA Advisory Program ...
trial.medpath.com · Nov 19, 2024
[2]
Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to ...
biospace.com · Oct 22, 2024

Alpha Tau Medical Ltd. accepted into FDA's Total Product Life Cycle Advisory Program Pilot to accelerate market access f...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy